Medical Devices

An expanded partnership aims to create next-gen cancer therapies by combining bispecific antibodies with two distinct drugs to overcome tumor resistance.

Major insurers now cover advanced AI plaque analysis, paving the way for personalized heart attack prevention and a new standard of cardiovascular care.

Kezar Life Sciences faces a critical FDA meeting for its novel liver disease drug, a decision that could bring hope to patients and define the company's future.

Sanuwave Health posts record revenue, defying industry-wide turmoil as reimbursement cuts reshape the advanced wound care market. How did they do it?

Belgian biotech MRM Health gets the green light for a Phase 2b trial of MH002, a novel 'living drug' aimed at revolutionizing ulcerative colitis care.

After an eight-year tenure marked by growth, CFO Todd Garner announces his departure. CONMED projects stability by reaffirming its 2025 financial outlook.

Kimball Electronics announces a major medical facility in Indianapolis and a rebrand to Kimball Solutions, a strategic pivot into the high-growth life sciences market.

Savara's potential new therapy for autoimmune PAP, MOLBREEVI, gets a powerful partner in PANTHERx Rare, promising a new era of comprehensive patient care.

The first system pairing a one-year implantable glucose monitor with an automated insulin pump is now available, promising to transform daily life for people with diabetes.

Alessa Therapeutics’ rice-sized implant, Enolen, earns FDA Fast Track, promising a new era for prostate cancer therapy without debilitating side effects.

As ENvue Medical prepares to ring the Nasdaq bell, a look at how its non-invasive tech for tube placement and pain relief is shaking up the MedTech world.

Record AI mega-deals redefine healthcare innovation, yet a broader market contraction creates a new divide for startups and traditional medical sectors.

With two key acquisitions, Currier Plastics expands its footprint and cleanroom capacity, signaling a major consolidation play by Sheridan Capital Partners.

With key studies now complete, Biofrontera's light-based therapy Ameluz could soon offer a new weapon against widespread actinic keratosis and stubborn acne.

NeuroSense adds world-renowned expert Prof. Steven Arnold to its board, a major vote of confidence in its multi-target Alzheimer's drug, PrimeC.

With a major cash infusion and key pipeline milestones, Xilio Therapeutics validates its tumor-activated approach to fighting cancer and extends its runway to 2027.

A new national reimbursement code for NeurAxis's IB-Stim therapy is set to revolutionize access for chronic GI pain patients, validating the technology.

The Spanish epigenetics leader will showcase its advanced CNS and oncology pipeline at key January conferences, seeking partners and investor validation.

A new study on a compact, wireless robotic device could democratize access to precision knee surgery, thanks to pioneering work from a rural Missouri surgeon.

With a key FDA meeting set, Trevi Therapeutics pushes its drug Haduvio into late-stage trials, offering hope for millions with no approved treatments.